Hormone sensitive prostate cancer

Czech version

Authors: Nikol Rušarová ^1,2; Marie Bartoušková ¹; Hana Študentová ¹
Authors‘ workplace: Onkologická klinika, Fakultní nemocnice v Olomouci ¹; Lékařská fakulta, Univerzita Palackého v Olomouci ²
Published in: Ces Urol 2019; 23(4): 309-315
Category: Review article

Overview

Prostate cancer is the second most common cancer in men worldwide and its incidence rises with age. Although most cases of prostate cancer are diagnosed and treated in early stage of disease, almost 10 % of patients have evidence of metastatic prostate cancer at presentation, and others develop disseminated disease after their definitive treatment. Contemporary research has led to the development of multiple active treatment modalities for men with advanced disease including combination of docetaxel or abiraterone with androgen deprivation therapy.

Keywords:

prostate cancer – androgen deprivation therapy – docetaxel – abiraterone

Sources

1. Dušek L, Mužík J, Kubásek M, et al. Epidemiologie zhoubných nádorů v České republice [on- line]. Masarykova univerzita [2005] [cit. 2018–12–28]. Dostupný z URL: http://www.svod.cz.

2. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effects of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–297.

3. Huggins C, Stevens J, Hodges CV. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941; 43: 209–223.

4. Kirby M, Hirst C, Crawford ED. Characterising the castration- resistant prostate cancer population: a systemic review. Int J Clin Pract. 2011; 65(11): 1180–1192.

5. Isaacs JT. The biology of hormone refraktory prostate cancer. Why does it develop? Clin North Am 1999; 26: 263–273.

6. Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351(15): 1502–1512.

7. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008; 26(2): 242–245.

8. Gravis G, Fizazi K, Joly F, et al. Androgen- deprivation therapy alone or with docetaxel in non- castrate metastatic prostate cancer (GETUG- AFU 15): a randomised, open- label, phase 3 trial. Lancet Oncol 2013; 14(2): 149–158.

9. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone -Sensitive Prostate Cancer. N Engl J Med 2015; 373(8): 737–746.

10. Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long- Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol 2018; 36(11): 1080–1087.

11. James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first- line long- term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016; 387(10024): 1163–1177.

12. Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy- naive men with metastatic castration- resistant prostate cancer (COU- AA-302): final overall survival analysis of a randomised, double- blind, placebo- controlled phase 3 study. Lancet Oncol 2015; 16: 152–160.

13. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration- resistant prostate cancer: fi nal overall survival analysis of the COU- AA-301 randomised, double- blind, placebo-controlled phase 3 study. Lancet Oncol. 2012; 13(10): 983–992.

14. Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration- Sensitive Prostate Cancer. N Engl J Med 2017; 377(4): 352–360.

15. James ND, de Bono JS, Spears MR, et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med 2017; 377(4): 338–351.

16. U.S. National Institutes of Health [online]. Home – ClinicalTrials.gov. [cit. 2018–12-20]. Dostupné z: https://clinicaltrials.gov/.